We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
-9.33%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$661M
AUM Growth
-$84.6M
Cap. Flow
-$6.68M
Cap. Flow %
-1.01%
Top 10 Hldgs %
76.63%
Holding
30
New
8
Increased
5
Reduced
6
Closed
8

Top Buys

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$49M
2
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$48.7M
3
NUVA
NuVasive, Inc.
NUVA
+$45.6M
4
ASRT
Assertio
ASRT
+$42.6M
5
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$39M

Top Sells

Rank Stock Value
1
INSY
Insys Therapeutics, Inc.
INSY
+$73.5M
2
AKRX
Akorn Inc
AKRX
+$70.7M
3
LCI
Lannett Company, Inc.
LCI
+$52.8M
4
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$45.2M
5
OSIR
Osiris Therapeutics, Inc. Common Stock
OSIR
+$23.3M

Sector Composition

Rank Sector Weight
1 Healthcare 90.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNK
1
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$68M 10.29%
1,110,000
+350,000
+46% +$22.4M
OFIX icon
2
Orthofix Medical
OFIX
$455M
$62.5M 9.46%
1,505,896
-343,500
-19% -$13.5M
MDVN
3
DELISTED
MEDIVATION, INC.
MDVN
$62.1M 9.39%
+1,350,000
New +$49M
IRWD icon
4
Ironwood Pharmaceuticals
IRWD
$611M
$54.1M 8.18%
+5,903,302
New +$48.7M
MACK
5
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$49.2M 7.44%
+746,734
New +$39M
NUVA
6
DELISTED
NuVasive, Inc.
NUVA
$48.9M 7.4%
+1,005,000
New +$45.6M
ABBV icon
7
AbbVie
ABBV
$458B
$47.6M 7.2%
833,000
+55,000
+7% +$3.07M
PACB icon
8
Pacific Biosciences
PACB
$422M
$38.4M 5.81%
4,517,517
-981,195
-18% -$9.65M
ASRT
9
DELISTED
Assertio
ASRT
$38.4M 5.81%
+45,939
New +$42.6M
TVTX icon
10
Travere Therapeutics
TVTX
$5.33B
$37.3M 5.64%
2,729,947
-730,376
-21% -$11.1M
ARIA
11
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$35.6M 5.39%
+5,575,742
New +$31.3M
ANIP icon
12
ANI Pharmaceuticals
ANIP
$1.77B
$34.6M 5.24%
1,028,364
+81,875
+9% +$2.78M
EGRX
13
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$28.1M 4.25%
693,937
-712,200
-51% -$45.2M
AGN
14
DELISTED
Allergan plc
AGN
$25.5M 3.85%
+95,000
New +$27.2M
VCEL icon
15
Vericel Corp
VCEL
$2.3B
$13.1M 1.98%
2,232,940
-120,000
-5% -$336K
ADMA icon
16
ADMA Biologics
ADMA
$1.92B
$8.58M 1.3%
1,060,017
– –
SPNE
17
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$2.45M 0.37%
167,298
+19,575
+13% +$272K
AXGN icon
18
Axogen
AXGN
$2.1B
$2.18M 0.33%
406,351
– –
PEN icon
19
Penumbra
PEN
$12.5B
$1.84M 0.28%
+40,000
New +$1.87M
BIOL
20
DELISTED
Biolase, Inc.
BIOL
$1.64M 0.25%
100
+12
+14% +$151K
VCYT icon
21
Veracyte
VCYT
$4.52B
$895K 0.14%
165,825
– –
DSCI
22
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$5K ﹤0.01%
181,818
-755,698
-81% -$2.53M
CPRX
23
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-2,888,942
Closed -$7.08M
VNDA icon
24
Vanda Pharmaceuticals
VNDA
$312M
– –
-1,093,696
Closed -$10.2M
LCI
25
DELISTED
Lannett Company, Inc.
LCI
– –
-329,175
Closed -$52.8M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q1 2016 Portfolio in Review

As of Q1 2016, Consonance Capital Management held 30 positions worth $661M, down 11% from $745M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Consonance Capital Management's Q1 2016 filing shows 8 new, 5 increased, 6 reduced and 8 closed positions. Its largest new stake was MEDIVATION, INC.: 1,350,000 shares worth $62.1M. The largest sale was Insys Therapeutics, Inc., an estimated $73.5M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 90% a quarter earlier.

  • Consonance Capital Management's largest Q1 2016 buy was MEDIVATION, INC.: 1,350,000 shares worth $62.1M.
  • Consonance Capital Management added most to MALLINCKRODT PUBLIC LIMITED COMPANY in Q1 2016, an estimated $22.4M increase.
  • Consonance Capital Management's biggest Q1 2016 reduction was Eagle Pharmaceuticals, Inc., cutting an estimated $45.2M.
  • Consonance Capital Management fully exited Insys Therapeutics, Inc. in Q1 2016, selling an estimated $73.5M.
  • Consonance Capital Management's ten largest holdings make up 77% of its $661M portfolio in Q1 2016.
  • Consonance Capital Management opened 8 new positions and closed 8 in Q1 2016.
  • Consonance Capital Management's portfolio value fell 11% quarter-over-quarter to $661M.

Based on Consonance Capital Management's 13F filing for Q1 2016, filed 16 May 2016.